Archives of Pharmacal Research

, Volume 34, Issue 11, pp 1773–1777 | Cite as

RETRACTED ARTICLE: SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease: First therapeutic application for the treatment of osteoarthritis

  • Sung-Yeol LeeEmail author
  • Hyoung-Keun Kwon
  • Sun-Mee Lee
Report on Investigational Drugs


SHINBARO is a purified extract from a mixture of 6 oriental herbs (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, and Eucommiae Cortex) that have been used as a traditional medicine for treatment of several inflammatory diseases and bone disorders. We determined antiinflammatory and antinociceptive activities of SHINBARO in adjuvant-induced (osteo)arthritis in rats. This potential anti-(osteo)arthritic property of SHINBARO can be due to the downregulation of inflammatory mediators such as iNOS, COX-2, and TNF-α, the increase of pain threshold in the peripheral system, the activation of alkaline phosphatase in osteoblasts, the suppression of proteoglycan degradation, and the inhibition of MMP-2 and MMP-9 activities as demonstrated by in vitro and in vivo experimental studies. We confirmed that SHINBARO is as effective as celecoxib, a selective COX-2 inhibitor, but it has the better safety profile in clinical trials. Finally, SHINBARO was approved as a New Herbal Medicine for treatment of osteoarthritis by Korean FDA on January 25th, 2011.


Herbal Medicine Celecoxib Oleanolic Acid Celecoxib Group Mellein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., and Schnitzer, T. J., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 343, 1520–1528 (2000).PubMedCrossRefGoogle Scholar
  2. Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Gimona, A., Matchaba, P., Hawkey, C. J., and Chesebro, J. H., Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet, 364, 675–684 (2004).PubMedCrossRefGoogle Scholar
  3. Farkouh, M. E., Greenberg, J. D., Jeger, R. V., Ramanathan, K., Verheugt, F. W., Chesebro, J. H., Kirshner, H., Hochman, J. S., Lay, C. L., Ruland, S., Mellein, B., Matchaba, P. T., Fuster, V., and Abramson, S. B., Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann. Rheum. Dis., 66, 764–770 (2007).PubMedCrossRefGoogle Scholar
  4. Hong, N. D., Rho, Y. S., Kim, J. W., Won, D. H., Kim, N. J., and Cho, B. S., Studies on the general pharmacological activities of Eucommia ulmoides Oliver. Kor. J. Pharmacogn, 19, 102–110 (1988).Google Scholar
  5. Ida, Y., Satoh, Y., Katsumata, M., Nagasao, M., Hirai, Y., Kajimoto, T., Katada, N., Yasuda, M., and Yamamoto, T., Two novel oleanolic acid saponins having a sialyl Lewis X mimetic structure from Achyranthes fauriei root. Bioorg. Med. Chem. Lett., 8, 2555–2558 (1998).PubMedCrossRefGoogle Scholar
  6. Kim, H. W., Kwon, Y. B., Ham, T. W., Roh, D. H., Yoon, S. Y., Han, H. J., Kang, S. K., Lee, H. J., Mar, W. C., Yang, I. S., Beitz, A. J., and Lee, J. H., The antinociceptive and antiinflammatory effect of ethylacetate extracts from Bang-Poong (Radix ledebouriellae) on the Freund’s adjuvantinduced arthritis in rats. J. Vet. Sci., 3, 343–349 (2002).PubMedGoogle Scholar
  7. Kim, S.-H., Lee, C.-H., Lee, J.-S., Cho, K.-H., Kim, S.-O., Cho, S.-H., Cho, H.-K., and Lee, S.-M., Anti-Inflammatory Activities of a Herbal Preparation GCSB-5 on Acute and Chronic Inflammation. Kor. J. Pharmacogn, 36, 311–317 (2005).Google Scholar
  8. Lee, C.-H., Kim, S.-H., Lee, J.-S., Cho, K.-H., Kim, J.-S., Cho, S.-H., and Lee, S.-M., Evaluation of the Antinociceptive Properties of GCSB-5, a Herbal Formulation. Kor. J. Pharmacogn, 36, 299–304 (2005).Google Scholar
  9. Weinberger, M., Tierney, W. M., Booher, P., and Katz, B. P., Can the provision of information to patients with osteoarthritis improve functional status? A randomized, controlled trial. Arthritis Rheum., 32, 1577–1583 (1989).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2011

Authors and Affiliations

  1. 1.Green CrossYonginKorea
  2. 2.School of PharmacySungkyunkwan UniversitySuwonKorea
  3. 3.Green CrossYonginKorea

Personalised recommendations